Chase Investment Counsel Corp Increases Position in AbbVie Inc. $ABBV

Chase Investment Counsel Corp raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 614.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,872 shares of the company’s stock after purchasing an additional 29,990 shares during the period. AbbVie makes up approximately 2.4% of Chase Investment Counsel Corp’s holdings, making the stock its 11th largest holding. Chase Investment Counsel Corp’s holdings in AbbVie were worth $8,074,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. bought a new stake in AbbVie in the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of AbbVie in the 3rd quarter valued at $41,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million build-out of two active pharmaceutical ingredient (API) facilities at its North Chicago campus to support next‑generation neuroscience and obesity medicines; expands domestic capacity and supports long‑term product supply and commercialization. AbbVie to Invest $380 Million in North Chicago
• Positive Sentiment: U.S. FDA approved the combination of Venclexta and acalabrutinib for previously untreated chronic lymphocytic leukemia (CLL), which could expand label use and drive additional oncology revenue. FDA approves Venclexta + acalabrutinib for CLL
• Positive Sentiment: Advanced ABBV‑8736 into a Phase 1 trial comparing injection routes (PK-focused) — early clinical progress that de‑risks part of the pipeline, though commercial impact is longer term and uncertain. AbbVie Advances ABBV-8736 With New Trial
• Positive Sentiment: Erste Group raised its FY2026 EPS forecast for AbbVie, lifting expectations for near‑term earnings which can support valuation and investor sentiment. AbbVie FY2026 EPS Forecast Boosted
• Neutral Sentiment: Industry talent movement: IDEAYA named a former AbbVie VP as Chief Development Officer — notable for personnel flow but unlikely to move AbbVie’s near‑term fundamentals. IDEAYA appoints ex‑AbbVie exec
• Negative Sentiment: Analyst commentary highlights a growth showdown with Johnson & Johnson and ongoing patent/competition risks — a reminder that AbbVie faces external pressures that could cap upside if key franchises weaken. Johnson & Johnson vs. AbbVie: A Growth Showdown

AbbVie Stock Performance

ABBV opened at $229.19 on Tuesday. The stock has a market capitalization of $405.07 billion, a PE ratio of 97.11, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The stock’s 50 day moving average price is $224.07 and its 200-day moving average price is $222.45. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Analysts Set New Price Targets

A number of brokerages recently commented on ABBV. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Citigroup lowered their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. BMO Capital Markets restated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $252.79.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.